» Articles » PMID: 9217810

Immunohistochemical Analysis of the Skin in Junctional Epidermolysis Bullosa Using Laminin 5 Chain Specific Antibodies is of Limited Value in Predicting the Underlying Gene Mutation

Overview
Journal Br J Dermatol
Specialty Dermatology
Date 1997 Jun 1
PMID 9217810
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The anchoring filament protein laminin 5 is composed of three polypeptide chains (alpha 3, beta 3 and gamma 2) each encoded by separate genes (LAMA3, LAMB3 and LAMC2, respectively). Mutations in any of these three genes may give rise to the autosomal recessive blistering skin disease, junctional epidermolysis bullosa. At present, there is no easy way of predicting which of these three genes might harbour the pathogenetic laminin 5 mutations in a case of junctional epidermolysis bullosa. In this study, we assessed whether immunohistochemistry might be helpful in this regard. We performed immunohistochemical labelling of the dermal-epidermal junction using alpha 3, beta 3 and gamma 2 chain-specific antibodies in 11 patients with junctional epidermolysis bullosa, in whom the laminin 5 mutations had been previously delineated. Although, labelling for the laminin 5 chain bearing the mutations was attenuated or undetectable in all cases, a complete absence of labelling or a reduction in the staining intensity for the other two chains was also seen in all cases. The results showed that immunohistochemical labelling of the dermal-epidermal junction using alpha 3, beta 3 and gamma 2 chain-specific antibodies is not a specific indicator for which of the laminin 5 chain genes contains the pathogenetic mutations, and is therefore unreliable in screening for individual laminin 5 gene mutations in cases of junctional epidermolysis bullosa.

Citing Articles

Complexity of Transcriptional and Translational Interference of Laminin-332 Subunits in Junctional Epidermolysis Bullosa with LAMB3 Mutations.

Hou P, Natsuga K, Tu W, Huang H, Chen B, Chen L Acta Derm Venereol. 2021; 101(8):adv00522.

PMID: 34231856 PMC: 9413659. DOI: 10.2340/00015555-3874.


Targeted next-generation sequencing identifies a novel mutation of LAMB3 in a Chinese neonatal patient presented with junctional epidermolysis bullosa.

Wang H, Yang Y, Zhou J, Cao J, He X, Li L Medicine (Baltimore). 2018; 97(49):e13225.

PMID: 30544381 PMC: 6310585. DOI: 10.1097/MD.0000000000013225.


Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa.

De Rosa L, Carulli S, Cocchiarella F, Quaglino D, Enzo E, Franchini E Stem Cell Reports. 2014; 2(1):1-8.

PMID: 24511464 PMC: 3916757. DOI: 10.1016/j.stemcr.2013.11.001.


Laminin 332 in junctional epidermolysis bullosa.

Kiritsi D, Has C, Bruckner-Tuderman L Cell Adh Migr. 2012; 7(1):135-41.

PMID: 23076207 PMC: 3544777. DOI: 10.4161/cam.22418.


Laminins in normal, keratoconus, bullous keratopathy and scarred human corneas.

Bystrom B, Virtanen I, Rousselle P, Miyazaki K, Linden C, Pedrosa Domellof F Histochem Cell Biol. 2007; 127(6):657-67.

PMID: 17492460 DOI: 10.1007/s00418-007-0288-4.